Search research articles
Contact Us
Filters
Showing results (141-150 of 156) with videos related to
Page
of 16
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 10, 2019
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
Byoung Chul Cho, Radka Obermannova, Alessandra Bearz, et al.
Lancet (London, England)
|
January 28, 2017
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Daniel S W Tan, Enriqueta Felip, Gilberto de Castro, et al.
Ecancermedicalscience
|
February 12, 2021
Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers
Milena Perez Mak, Fatima Solange Pasini, Lixia Diao, et al.
Critical Reviews in Oncology/Hematology
|
May 10, 2025
Preoperative neoadjuvant chemotherapy or immunotherapy in head and neck cancer: A systematic review and meta-analysis of surgical risk and pathologic response
Caique Mariano Pedroso, Mariana de Pauli Paglioni, Ana Gabriela Costa Normando, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 28, 2017
A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial
Gilberto de Castro Junior, José Getúlio Segalla, Sérgio Jobim de Azevedo, et al.
The Lancet. Oncology
|
February 22, 2015
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study
Luis Paz-Ares, Jörg Mezger, Tudor E Ciuleanu, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
October 28, 2021
Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial
Elisa Kauark-Fontes, Cesar Augusto Migliorati, Joel B Epstein, et al.
The New England Journal of Medicine
|
May 29, 2026
First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion Mutations
Caicun Zhou, Laurent Greillier, Geoffrey Liu, et al.
JTO Clinical and Research Reports
|
March 4, 2024
Health Services Access Inequalities in Brazil Result in Poorer Outcomes for Stage III NSCLC-RELANCE/LACOG 0118
Vladmir C Cordeiro de Lima, Ana Gelatti, José F P Moura, et al.
Page
of 16
Search research articles
Search
Showing results (141-150 of 156) with videos related to
Sort By:
Page
of 16
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 10, 2019
Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study
Byoung Chul Cho, Radka Obermannova, Alessandra Bearz, et al.
Lancet (London, England)
|
January 28, 2017
First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
Jean-Charles Soria, Daniel S W Tan, Rita Chiari, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 1, 2023
Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial
Daniel S W Tan, Enriqueta Felip, Gilberto de Castro, et al.
Ecancermedicalscience
|
February 12, 2021
Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers
Milena Perez Mak, Fatima Solange Pasini, Lixia Diao, et al.
Critical Reviews in Oncology/Hematology
|
May 10, 2025
Preoperative neoadjuvant chemotherapy or immunotherapy in head and neck cancer: A systematic review and meta-analysis of surgical risk and pathologic response
Caique Mariano Pedroso, Mariana de Pauli Paglioni, Ana Gabriela Costa Normando, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 28, 2017
A randomised phase II study of chemoradiotherapy with or without nimotuzumab in locally advanced oesophageal cancer: NICE trial
Gilberto de Castro Junior, José Getúlio Segalla, Sérgio Jobim de Azevedo, et al.
The Lancet. Oncology
|
February 22, 2015
Necitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study
Luis Paz-Ares, Jörg Mezger, Tudor E Ciuleanu, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
October 28, 2021
Extraoral photobiomodulation for prevention of oral and oropharyngeal mucositis in head and neck cancer patients: interim analysis of a randomized, double-blind, clinical trial
Elisa Kauark-Fontes, Cesar Augusto Migliorati, Joel B Epstein, et al.
The New England Journal of Medicine
|
May 29, 2026
First-Line Sunvozertinib in NSCLC with <i>EGFR</i> Exon 20 Insertion Mutations
Caicun Zhou, Laurent Greillier, Geoffrey Liu, et al.
JTO Clinical and Research Reports
|
March 4, 2024
Health Services Access Inequalities in Brazil Result in Poorer Outcomes for Stage III NSCLC-RELANCE/LACOG 0118
Vladmir C Cordeiro de Lima, Ana Gelatti, José F P Moura, et al.
Page
of 16